Hikal Ltd
Hikal Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Expect strong recovery in H2 FY26 with ramp-up in deliveries post-US FDA remediation (Page 4, 13). Hikal expects a strong recovery in H2 FY26, with resumed deliveries and ramp-up in pharmaceutical business following resolution of US FDA warning letter issues.
From Hikal Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Expect strong recovery in H2 FY26 with ramp-up in deliveries post-US FDA remediation (Page 4, 13).
- Aim to hold full-year guidance of double-digit growth in pharma despite 1H challenges (Page 14).
- New molecules and product launches projected annually (2-3 new products) supporting medium-term growth (Page 6).
- Robust development pipelines with 8-9 molecules progressing well; peak food and nutraceutical output expected in 18-24 months (Page 6).
- Increasing CDMO early-stage RFPs and transitioning projects from development to pilot scale (Page 6).
- Crop protection volumes starting to recover; flat sales expected full year (Page 5).
- Animal health segment to ramp up commercial supplies over next 1-2 quarters with strong development pipeline (Pages 5, 21).
- Investment in new capabilities and high-potency labs to support future growth in niche segments like oncology APIs (Pages 5, 21).
- Conversion rate of pharma RFPs improving, with expected scale-up of development revenues (Page 16).
Profitability & Margins
See what Hikal Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capital expenditure (CAPEX) in H1 FY 2026 stood at Rs. 65 crores, focused on debottlenecking, regulatory upgrades, and expanding CDMO capacity.
- Full-year CAPEX guidance is maintained at Rs. 200 crores, emphasizing disciplined allocation toward high ROI projects aligned with long-term growth strategy.
- Investments include repurposing a large plant from specialty chemicals to fully pharma assets, with Phase 1 completing by end FY 2026 and Phase 2 by end calendar year, enabling capacity for new molecules.
- New pilot-scale capacity is being set up at the Pune R&D center to support growth in food and nutraceutical ingredients.
- Investment in a High Potent Active Pharma Ingredient (HP API) lab to enter rapidly growing segments like Oncology APIs.
- Ongoing efforts include remediation CAPEX to comply with FDA requirements at Bangalore facility.
- Expansion of business development manpower globally to capitalize on new opportunities.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hikal Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has seen several inquiries and RFPs from both mid-size and small-size companies, especially in the pharma CDMO segment.
- Approximately $4 to $5 million in development revenue is expected from these new customers in the current year, with potential for scaling up.
- The RFP conversion rate is typically between 15% to 20%, with plans to improve this to 20%-25% through enhanced BD efforts.
- In the animal health segment, pre-commercial quantities are being supplied with registrations progressing; growth is anticipated as registrations complete.
- No cancellations of existing purchase orders were reported despite regulatory challenges; some sales deferred but expected to be fulfilled soon.
- Several new development contracts and shortlisted RFPs indicate a strong and diversified project pipeline.
Hikal Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹519 Cr, net profit ₹14 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hikal Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Alivus Life Sciences Ltd (Q2 FY26)
Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Key concall takeaways from Alivus Life's Q2 FY26 earnings call — and how it ranks against sector…
- Solara Active Pharma Sciences Ltd (Q2 FY26)
Current facility capacity utilization is about 70%, with capacity available to serve new customers. Key concall takeaways from Solara Active's Q2 FY26 earnings…
- Sun Pharmaceutical Industries Ltd (Q2 FY26)
India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Key concall…
- Zydus Lifesciences Ltd (Q2 FY26)
Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…
Frequently Asked Questions
What were Hikal Ltd Q2 FY26 results?
Expect strong recovery in H2 FY26 with ramp-up in deliveries post-US FDA remediation (Page 4, 13). Hikal expects a strong recovery in H2 FY26, with resumed deliveries and ramp-up in pharmaceutical business following resolution of US FDA warning letter issues.
What is Hikal Ltd share price analysis?
Hikal Ltd currently shows a neutral. The stock trades at a P/E of 63.4 with a market cap of ₹2,688 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hikal Ltd planning capital expenditure?
Capital expenditure (CAPEX) in H1 FY 2026 stood at Rs.
Keep Hikal Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.